Brussels, Belgium, Belgium · Est. 1868 · 8,000 employees
UCB is a biopharmaceutical company focused on discovering and developing innovative medicines in immunology and neurology.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 6 drugs with upcoming expirations
Pipeline
By Phase
7 drugs in development
By Therapeutic Area
top 2
R&D Momentum
64/100
Pipeline Velocity
36/100
Trial Completion Rate
89/100
Pipeline Concentration
63/100
Pipeline Freshness
79/100
Strategic Signals
Activity
Last 14 days
A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndrome
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis (SCALA)
An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis (ATMOS)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Details
Company Overview
$20.0B
Mkt Cap
$5.3B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Keppra — ELEPSIA XR
Application NDA204417 (NDA)
Keppra — ELEPSIA XR
Application NDA204417 (NDA)
Cimzia — CIMZIA
Application BLA125160
Cimzia — CIMZIA
Application BLA125160
Cimzia — CIMZIA
Application BLA125160
Fintepla — FINTEPLA
Application NDA212102 (NDA)
Cimzia — CIMZIA
Application BLA125160
Cimzia — CIMZIA
Application BLA125160
Zilbrysq — ZILBRYSQ
Application NDA216834 (NDA)
Bimzelx — BIMZELX
Application BLA761151
Bimzelx — BIMZELX
Application BLA761151 (BLA)
Rysodeg — RYSTIGGO
Application BLA761286 (BLA)
Vimpat — MOTPOLY XR
Application NDA216185 (NDA)
Bimzelx — BIMZELX
Application BLA761151
Bimzelx — BIMZELX
Application BLA761151
Bimzelx — BIMZELX
Application BLA761151
Bimzelx — BIMZELX
Application BLA761151
Bimzelx — BIMZELX
Application BLA761151
Cimzia — CIMZIA
Application BLA125160
Cimzia — CIMZIA
Application BLA125160
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)